Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 3Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Myelodysplastic Syndromes 26Hematologic Neoplasms 20Lymphoma, Non-Hodgkin 19Multiple Myeloma 18Lymphoma 18Recurrence 15Lymphoma, B-Cell 14Lymphoma, Large B-Cell, Diffuse 13Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Breast Neoplasms 11Pancreatic Neoplasms 10Ovarian Neoplasms 10Lymphoma, Follicular 10Neoplasm Metastasis 9Melanoma 9Leukemia, Myelomonocytic, Chronic 9Myeloproliferative Disorders 8Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 7Leukemia, Biphenotypic, Acute 7Leukemia 7Hodgkin Disease 7Glioblastoma 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Osteosarcoma 6

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Cyclophosphamide 9Prednisone 8Doxorubicin 7Vincristine 6Azacitidine 5pembrolizumab 3fludarabine 3belinostat 3Lenalidomide 3Brentuximab Vedotin 310-propargyl-10-deazaaminopterin 3ruxolitinib 2duvelisib 2Gemcitabine 2Dexamethasone 2Biopsy 2Bendamustine Hydrochloride 2venetoclax 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1pomalidomide 1ixazomib 1ivarmacitinib 1daratumumab 1cemiplimab 1calaspargase pegol 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, T-Cell, Peripheral × fludarabine × Clear all
NCT07055477 2026-05-22

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
60 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT04083495 2025-09-22

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT06468267 2024-08-01

RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
50 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡